Doxorubicin Hydrochloride Injectable, Liposomal
Product Images NDC 72603-200

9 FDA label images from Northstar Rxllc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 72603-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-doxorubicin-structure (Spl Doxorubicin Structure)

Spl-doxorubicin-structure (Spl Doxorubicin Structure)
Chemical structure diagram of Doxorubicin Hydrochloride depicting the molecular arrangement including hydroxyl, methoxy, and amine functional groups along with the hydrochloride (HCl) component.*
FDA Label Image

Spl-doxorubicin-structure1 (Spl Doxorubicin Structure1)

Spl-doxorubicin-structure1 (Spl Doxorubicin Structure1)
Chemical structure of MPEG-DSPE, a compound shown in the structural formula illustration with its chemical groups and phosphate moiety detailed.*
FDA Label Image

Spl-doxorubicin-structure2 (Spl Doxorubicin Structure2)

Spl-doxorubicin-structure2 (Spl Doxorubicin Structure2)
Chemical structure diagram labeled as HSPC, showing a phospholipid with quaternary ammonium, phosphate, glycerol, and fatty acid chains of variable lengths (m,n = 14 or 16).*
FDA Label Image

Spl-doxorubicin-figure (Spl Doxorubicin Figure)

Spl-doxorubicin-figure (Spl Doxorubicin Figure)
An illustration depicting the structure of a pegylated liposome used for Doxorubicin Hydrochloride injectable. The diagram labels the MPEG-DSPE coating on the outer surface, the liposomal bilayer, and the aqueous core containing entrapped doxorubicin HCl in the center.*
FDA Label Image

Spl-doxorubicin-figure1 (Spl Doxorubicin Figure1)

Spl-doxorubicin-figure1 (Spl Doxorubicin Figure1)
A Kaplan-Meier survival curve comparing the percent of subjects progression-free over 15 months for two treatment groups: Doxorubicin plus Bortezomib and Bortezomib alone. The graph shows higher progression-free survival for the combination therapy group. Number of subjects at risk at various time points is listed below the graph, along with statistical values including p-value and hazard ratio (HR).*
FDA Label Image

Doxo-label-20mg-10ml (Doxo Label 20mg 10ml)

Doxo-label-20mg-10ml (Doxo Label 20mg 10ml)
Label for Doxorubicin Hydrochloride Liposome Injection 2 mg/mL (10 mg/10 mL), injectable liposomal formulation for intravenous use. The label indicates it is a cytotoxic agent, must be diluted, and is supplied in a sterile 10 mL single-dose vial. Manufactured for NorthStar Rx LLC with storage instructions and lot/expiration date fields visible.*
FDA Label Image

Doxo-carton-20mg-10ml (Doxo Carton 20mg 10ml)

Doxo-carton-20mg-10ml (Doxo Carton 20mg 10ml)
Packaging label for Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) injectable liposomal formulation. The label includes the proprietary and generic names, dosage strength, form as a single-dose vial for intravenous use, manufacturer information (Northstar Rx LLC and Sun Pharmaceutical Industries Ltd.), and instructions highlighting dilution prior to administration and storage conditions. The package design features purple, green, and white colors with regulatory information and barcode.*
FDA Label Image

Doxo-label-50mg-25ml (Doxo Label 50mg 25ml)

Doxo-label-50mg-25ml (Doxo Label 50mg 25ml)
Label for Doxorubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) in a 25 mL single-dose vial. The label indicates it is a cytotoxic agent, liposomal formulation, for intravenous infusion only after dilution, sterile, and includes warnings not to substitute for Doxorubicin Hydrochloride. Manufactured for Northstar Rx LLC and by Sun Pharmaceutical Industries in India.*
FDA Label Image

Doxo-carton-50mg-25ml (Doxo Carton 50mg 25ml)

Doxo-carton-50mg-25ml (Doxo Carton 50mg 25ml)
Packaging label for Doxorubicin Hydrochloride Liposome Injection, 50 mg/25 mL (2 mg/mL) sterile injectable liposomal formulation by NorthStar RxLLC. The label includes administration instructions, storage conditions at 2°C to 8°C, and a warning that it must be diluted prior to intravenous infusion. Manufactured by Sun Pharmaceutical Ind. Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.